201 related articles for article (PubMed ID: 12584149)
1. Assessment of the contributions of CYP3A4 and CYP3A5 in the metabolism of the antipsychotic agent haloperidol to its potentially neurotoxic pyridinium metabolite and effect of antidepressants on the bioactivation pathway.
Kalgutkar AS; Taylor TJ; Venkatakrishnan K; Isin EM
Drug Metab Dispos; 2003 Mar; 31(3):243-9. PubMed ID: 12584149
[TBL] [Abstract][Full Text] [Related]
2. Cytochrome P450-mediated metabolism of haloperidol and reduced haloperidol to pyridinium metabolites.
Avent KM; DeVoss JJ; Gillam EM
Chem Res Toxicol; 2006 Jul; 19(7):914-20. PubMed ID: 16841959
[TBL] [Abstract][Full Text] [Related]
3. Studies on the conversion of haloperidol and its tetrahydropyridine dehydration product to potentially neurotoxic pyridinium metabolites by human liver microsomes.
Usuki E; Pearce R; Parkinson A; Castagnol N
Chem Res Toxicol; 1996 Jun; 9(4):800-6. PubMed ID: 8831826
[TBL] [Abstract][Full Text] [Related]
4. Studies on the metabolism of haloperidol (HP): the role of CYP3A in the production of the neurotoxic pyridinium metabolite HPP+ found in rat brain following ip administration of HP.
Igarashi K; Kasuya F; Fukui M; Usuki E; Castagnoli N
Life Sci; 1995 Nov; 57(26):2439-46. PubMed ID: 8847965
[TBL] [Abstract][Full Text] [Related]
5. Identification of an N-methyl-4-phenylpyridinium-like metabolite of the antidiarrheal agent loperamide in human liver microsomes: underlying reason(s) for the lack of neurotoxicity despite the bioactivation event.
Kalgutkar AS; Nguyen HT
Drug Metab Dispos; 2004 Sep; 32(9):943-52. PubMed ID: 15319335
[TBL] [Abstract][Full Text] [Related]
6. In vitro characterization of the oxidation of a pyridinium metabolite of haloperidol by human placenta: the effect of smoking.
Fang J; Song J
J Pharm Pharm Sci; 2012; 15(4):538-47. PubMed ID: 23106957
[TBL] [Abstract][Full Text] [Related]
7. In vitro characterization of the metabolism of haloperidol using recombinant cytochrome p450 enzymes and human liver microsomes.
Fang J; McKay G; Song J; Remillrd A; Li X; Midha K
Drug Metab Dispos; 2001 Dec; 29(12):1638-43. PubMed ID: 11717183
[TBL] [Abstract][Full Text] [Related]
8. Neurotoxic pyridinium metabolites of haloperidol are substrates of human organic cation transporters.
Kang HJ; Lee SS; Lee CH; Shim JC; Shin HJ; Liu KH; Yoo MA; Shin JG
Drug Metab Dispos; 2006 Jul; 34(7):1145-51. PubMed ID: 16624869
[TBL] [Abstract][Full Text] [Related]
9. CYP2C8 and CYP3A4 are the principal enzymes involved in the human in vitro biotransformation of the insulin secretagogue repaglinide.
Bidstrup TB; Bjørnsdottir I; Sidelmann UG; Thomsen MS; Hansen KT
Br J Clin Pharmacol; 2003 Sep; 56(3):305-14. PubMed ID: 12919179
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetic determinants of human liver microsomal alfentanil metabolism and the role of cytochrome P450 3A5.
Klees TM; Sheffels P; Thummel KE; Kharasch ED
Anesthesiology; 2005 Mar; 102(3):550-6. PubMed ID: 15731592
[TBL] [Abstract][Full Text] [Related]
11. Metabolism of the active metabolite of quetiapine, N-desalkylquetiapine in vitro.
Bakken GV; Molden E; Knutsen K; Lunder N; Hermann M
Drug Metab Dispos; 2012 Sep; 40(9):1778-84. PubMed ID: 22688609
[TBL] [Abstract][Full Text] [Related]
12. Interaction of cisapride with the human cytochrome P450 system: metabolism and inhibition studies.
Desta Z; Soukhova N; Mahal SK; Flockhart DA
Drug Metab Dispos; 2000 Jul; 28(7):789-800. PubMed ID: 10859153
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cytochrome P-450-dependent metabolism and drug interactions of the 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors lovastatin and pravastatin in the liver.
Jacobsen W; Kirchner G; Hallensleben K; Mancinelli L; Deters M; Hackbarth I; Benet LZ; Sewing KF; Christians U
Drug Metab Dispos; 1999 Feb; 27(2):173-9. PubMed ID: 9929499
[TBL] [Abstract][Full Text] [Related]
14. The kinetics of aflatoxin B1 oxidation by human cDNA-expressed and human liver microsomal cytochromes P450 1A2 and 3A4.
Gallagher EP; Kunze KL; Stapleton PL; Eaton DL
Toxicol Appl Pharmacol; 1996 Dec; 141(2):595-606. PubMed ID: 8975785
[TBL] [Abstract][Full Text] [Related]
15. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
Ma B; Polsky-Fisher SL; Vickers S; Cui D; Rodrigues AD
Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of human cytochrome P450 isoforms interacting with pimozide.
Desta Z; Kerbusch T; Soukhova N; Richard E; Ko JW; Flockhart DA
J Pharmacol Exp Ther; 1998 May; 285(2):428-37. PubMed ID: 9580580
[TBL] [Abstract][Full Text] [Related]
17. The involvement of CYP1A2 and CYP3A4 in the metabolism of clozapine.
Eiermann B; Engel G; Johansson I; Zanger UM; Bertilsson L
Br J Clin Pharmacol; 1997 Nov; 44(5):439-46. PubMed ID: 9384460
[TBL] [Abstract][Full Text] [Related]
18. Brain extraction of 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]pyridinium ion (HPP+), a neurotoxic metabolite of haloperidol: studies using [3H]HPP+.
Kawashima H; Iida Y; Kitamura Y; Kiyono Y; Magata Y; Saji H
Jpn J Pharmacol; 2002 Aug; 89(4):426-8. PubMed ID: 12233823
[TBL] [Abstract][Full Text] [Related]
19. Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes.
Lalovic B; Phillips B; Risler LL; Howald W; Shen DD
Drug Metab Dispos; 2004 Apr; 32(4):447-54. PubMed ID: 15039299
[TBL] [Abstract][Full Text] [Related]
20. Comparative metabolic capabilities of CYP3A4, CYP3A5, and CYP3A7.
Williams JA; Ring BJ; Cantrell VE; Jones DR; Eckstein J; Ruterbories K; Hamman MA; Hall SD; Wrighton SA
Drug Metab Dispos; 2002 Aug; 30(8):883-91. PubMed ID: 12124305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
